ISM-001 is under clinical development by InSilico Medicine and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ISM-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ISM-001055 is under development for the treatment of idiopathic pulmonary fibrosis (IPF), kidney fibrosis and skin fibrosis. It is administered through intravenous route. The therapeutic candidate is developed based on Pharma AI (artificial intelligence) platform.
InSilico Medicine overview
InSilico Medicine (InSilico) is an artificial intelligence-driven pharma-technology company that focuses on accelerating drug discovery and development. It provides integrated drug discovery software suite products including PandaOmics, multi-omics target discovery and deep biology analysis engine to discover novel targets. The company offers Chemistry 42, a machine learning de-novo drug design engineering platform to generate novel molecules; and Inclinico, to design and predict clinical trials. InSilico works in collaboration with pharmaceutical companies to develop drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s disease, Alzheimer’s disease, diabetes, sarcopenia, aging and others. It operates in Hong Kong and the US. InSilico is headquartered in Hong Kong.
For a complete picture of ISM-001’s drug-specific PTSR and LoA scores, buy the report here.